Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

BioDrugs(2020)10.1007/s40259-020-00412-3Source: DataRank Database

In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies is a research paper published in BioDrugs (2020). On theSindex it has a DataRank of 0. It has been cited 70 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access70 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 6.42)OA: hybridTopics (60)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Mamadou A. Bah ORCID,David B. Weiner ORCID,Ami Patel ORCID

Live enrichment

PubMed:32157600 PMC:PMC7211204 OpenAlex:https://openalex.org/W3011544836

Bill and Melinda Gates Foundation

Grant: OPP1163327

Bill and Melinda Gates Foundation

Grant: OPP1201239

National Institutes of Health

Grant: R01AI141236

National Institutes of Health

Grant: U19 AI142777

NCI NIH HHS

Grant: P30 CA010815

National Institutes of Health

Grant: 1R01AI141236-01

Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection

National Institutes of Health

Grant: 5U19AI142777-04

Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

FWCI

6.42

Citation Percentile

1.0%

Influential Citations

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s40259-020-00412-3.pdf

HYBRIDhttps://link.springer.com/content/pdf/10.1007/s40259-020-00412-3.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40259-020-00412-3.pdf

publisherhttp://link.springer.com/content/pdf/10.1007/s40259-020-00412-3.pdf

publisherhttp://link.springer.com/article/10.1007/s40259-020-00412-3/fulltext.html

Fields of Study

Virus-based gene therapy researchRNA Interference and Gene DeliveryBacteriophages and microbial interactionsMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsAntibodies, MonoclonalBenzenesulfonatesDNADrug CarriersGene Transfer TechniquesGenetic TherapyGenetic VectorsImmunotherapyMiceNucleic AcidsRNA, Messenger

MeSH Terms

AnimalsAntibodies, MonoclonalBenzenesulfonatesDNADrug CarriersGenetic VectorsImmunotherapyNucleic AcidsRNA, MessengerGenetic TherapyGene Transfer TechniquesMice

Keywords

Monoclonal antibodyGene deliveryNucleic acidComputational biologyGenetic enhancementBiologyIn vivoPlasmidViral vectorBiotechnologyAntibodyDNAGeneImmunologyRecombinant DNAGeneticsDrug CarriersBenzenesulfonatesGenetic VectorsGene Transfer TechniquesAntibodies, MonoclonalLeading ArticleGenetic TherapyMiceNucleic AcidsAnimalsImmunotherapyRNA, Messenger

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice